The value of postoperative radiotherapy in thymoma patients with myasthenia gravis

Chen, Liu; Li, Yang; Dong, Xiaohua; Tanzhu, Guilong; Chu, Xianjing; Deng, Fuxing; Li, Xiang; Zhang, Jing; Lü, Bin; Jiang, Di; Niu, Lishui; Peng, Haiqin; Yang, Huan; Zhou, Rongrong

doi:10.1016/j.radonc.2023.109644

Cited by 4 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, some population-based studies found no significant difference in OS or freedom from recurrence in stage II patients who received adjuvant radiation after surgery [35,36]. In summary, although PORT is controversial in patients with R0 resection, it is highly recommended for patients with thymomas who underwent incomplete resection, especially for patients with advanced thymomas [37][38][39]. In our study, although there was no significant difference between elderly thymoma patients who received PORT and those who did not, the risk of OS in patients who received PORT tended to decrease (HR = 0.83, p = 0.445).…”

Section: Discussionmentioning

confidence: 99%

Clinical Features, Treatment Modalities, and Outcomes of Elderly Thymoma Patients: A Propensity-Matched Study Based on the SEER Database

Wang,

Gong,

Zhang

et al. 2023

Oncol Res Treat

View full text Add to dashboard Cite

Introduction: Thymoma is a common mediastinal tumor, but few studies have been performed in thymoma patients 80 years or older. This study aimed to analyze the clinical features, treatment modalities and survival outcomes of thymoma patients at least 80 years old and compare these features to those of patients younger than 80 years old. Method: Data from thymoma patients in the Surveillance, Epidemiology and End Results database between 2000 and 2019 were selected. Clinical features, treatment modalities of the two age groups were compared. Survival rates were calculated by the Kaplan-Meier method and the log-rank test was used to compare survival rates between two groups. Propensity score matching was used based on whether surgery was performed. Univariate and multivariate Cox proportional–hazards regression analyses were performed to identify independent prognostic factors. Results: Compared with the younger patients, the patients aged 80 years or older had a similar distribution of Masaoka–Koga tumor stage, a higher proportion of type A thymoma, and a lower recurrence rate in the early stage. In elderly patients after propensity score matching, the overall survival and cancer–specific survival were better in the surgery group with complete resection and similar benefit from surgery as younger patients were observed. Conclusion: In thymoma patients aged 80 years or older, surgery still plays an important role in survival outcome. Compared with younger patients, older patients had unique clinical features.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Features, Treatment Modalities, and Outcomes of Elderly Thymoma Patients: A Propensity-Matched Study Based on the SEER Database

Wang,

Gong,

Zhang

et al. 2023

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Daily portal controls are recommended as per the protocol. Additionally, monthly quality assurance meetings should be organized involving radiation oncologists participating in the randomized trials [ 37 – 39 ].…”

Section: Design Of Radiation Fieldsmentioning

confidence: 99%

Radiotherapy for tumors of the mediastinum – state of the art

Kantzou,

Sarris,

Kouloulias

et al. 2023

kitp

View full text Add to dashboard Cite

Mediastinal tumors encompass a diverse range of malignancies, originating within or spreading to the mediastinum. The administration of radiotherapy within the anatomical confines of the mediastinum presents unique challenges owing to the close proximity of critical organs, including the heart, lungs, esophagus, and spinal cord. However, recent progress in imaging techniques, treatment modalities, and our understanding of tumor biology has significantly contributed to the development of effective and safe therapeutic strategies for mediastinal diseases. This review article aims to explore the latest innovations in radiotherapy and their practical applications in the management of mediastinal tumors, with a primary focus on lymphomas, thymomas, and thymic carcinomas. By examining these advancements, we seek to provide valuable insights into the current state of the art in radiotherapy for mediastinal malignancies, ultimately fostering improved patient outcomes and clinical decision-making.

show abstract

Metastatic brain tumors: from development to cutting‐edge treatment

Tanzhu,

Chen,

Ning

et al. 2024

MedComm

View full text Add to dashboard Cite

Metastatic brain tumors, also called brain metastasis (BM), represent a challenging complication of advanced tumors. Tumors that commonly metastasize to the brain include lung cancer and breast cancer. In recent years, the prognosis for BM patients has improved, and significant advancements have been made in both clinical and preclinical research. This review focuses on BM originating from lung cancer and breast cancer. We briefly overview the history and epidemiology of BM, as well as the current diagnostic and treatment paradigms. Additionally, we summarize multiomics evidence on the mechanisms of tumor occurrence and development in the era of artificial intelligence and discuss the role of the tumor microenvironment. Preclinically, we introduce the establishment of BM models, detailed molecular mechanisms, and cutting‐edge treatment methods. BM is primarily treated with a comprehensive approach, including local treatments such as surgery and radiotherapy. For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. Multiomics approaches assist in clinical diagnosis and treatment, revealing the complex mechanisms of BM. Moreover, preclinical agents often need to cross the blood–brain barrier to achieve high intracranial concentrations, including small‐molecule inhibitors, nanoparticles, and peptide drugs. Addressing BM is imperative.

show abstract

The value of postoperative radiotherapy in thymoma patients with myasthenia gravis

Cited by 4 publications

References 41 publications

Clinical Features, Treatment Modalities, and Outcomes of Elderly Thymoma Patients: A Propensity-Matched Study Based on the SEER Database

Clinical Features, Treatment Modalities, and Outcomes of Elderly Thymoma Patients: A Propensity-Matched Study Based on the SEER Database

Radiotherapy for tumors of the mediastinum – state of the art

Metastatic brain tumors: from development to cutting‐edge treatment

Contact Info

Product

Resources

About